Bausch + Lomb Launches Proposed Financing for Xiidra Acquisition
By Robb M. Stewart
Bausch + Lomb is offering $1.4 billion in debt and is looking to secure an incremental term loan facility to help finance the planned acquisition of a dry-eye drug from Novartis.
The eye-care company said Monday a wholly owned subsidiary has launched an offering of new senior secured notes due 2028 to fund the proposed purchase of Xiidra, Novartis's non-steroid eye drop approved to treat the signs and symptoms of dry eye disease, for $1.75 billion in cash, plus possible milestone payments based on sales and pipeline commercialization.
Bausch + Lomb also is seeking to enter into the term loan facility that could in the form of an incremental amendment to its existing credit agreement or a separate credit agreement. The company said it expects to borrow $500 million of new term B loans under the facility.
The deal for Xiidra was first big move by Chief Executive Brent Saunders since he returned to the helm in March. Bausch + Lomb has said the acquisition, which it expects to close by the end of the year, will be immediately accretive.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
September 11, 2023 07:43 ET (11:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth